Sivakumaran Devarajan

Learn More
Depression is one of the most common illnesses and is very debilitating, but unfortunately, its treatment remains unsatisfactory. Despite adequate and optimum therapeutic interventions, only about 70% show a response to treatment and only about 40% reach full remission (Cowen 1996; Chehil et al. 2000). Up to 30% of patients fall into the category of(More)
We report two patients who developed a severe discontinuation (withdrawal) reaction following stoppage of paroxetine and venlafaxine, respectively. Neurological symptoms were prominent and neither patient could walk unaided. Both patients feared they had suffered a 'stroke' and arranged an emergency medical consultation. One patient was correctly diagnosed,(More)
BACKGROUND Partial or total overnight sleep deprivation produces immediate mood improvement in about 50% of patients with depression, but not in healthy controls. Our objectives were to compare the neurochemical changes that accompanied partial overnight sleep deprivation in healthy and depressed participants, and to compare baseline neurochemical profiles(More)
We describe the successful treatment of five patients with treatment-resistant major depressive disorder (TR-MDD) with a combination pharmacotherapy of pindolol, tryptophan and nefazodone. Five TR-MDD outpatients who had previously not responded to at least four different antidepressant medication trials were initiated on 300 mg/day of nefazodone, 7.5(More)